1. Home
  2. RXRX vs NTLA Comparison

RXRX vs NTLA Comparison

Compare RXRX & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Recursion Pharmaceuticals Inc.

RXRX

Recursion Pharmaceuticals Inc.

HOLD

Current Price

$3.74

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$11.97

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RXRX
NTLA
Founded
2013
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
RXRX
NTLA
Price
$3.74
$11.97
Analyst Decision
Buy
Buy
Analyst Count
4
23
Target Price
$7.50
$20.02
AVG Volume (30 Days)
14.7M
3.3M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
14.79
27.43
EPS
N/A
N/A
Revenue
$74,681,000.00
$67,671,000.00
Revenue This Year
$12.11
N/A
Revenue Next Year
$82.52
$62.75
P/E Ratio
N/A
N/A
Revenue Growth
26.92
16.92
52 Week Low
$2.77
$7.95
52 Week High
$7.18
$28.24

Technical Indicators

Market Signals
Indicator
RXRX
NTLA
Relative Strength Index (RSI) 59.36 46.97
Support Level $2.87 $11.55
Resistance Level $4.03 $13.88
Average True Range (ATR) 0.19 0.53
MACD 0.02 -0.08
Stochastic Oscillator 95.90 40.92

Price Performance

Historical Comparison
RXRX
NTLA

About RXRX Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: